Data & Statistics on Hemophilia
In the United States
- Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year.
- The exact number of people living with hemophilia in the United States is not known. A CDC study conducted in six states in 1994 estimated that about 17,000 people had hemophilia at that time. Currently, the number of people with hemophilia in the United States is estimated to be about 20,000, based on expected births and deaths since 1994.
- In the United States, most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia.
- In about two thirds of cases, there is a family history of hemophilia. The diagnosis of hemophilia is made using a special blood test and most babies can be tested soon after birth. Sometimes prenatal genetic testing is done to diagnose hemophilia before birth.
- For the one-third of babies born with hemophilia in families with no known history of hemophilia, the diagnosis is made when an unusual bleeding event occurs. Special blood tests are required to make the diagnosis.
- A CDC-sponsored randomized clinical trial found that children who were treated on a regular basis to prevent bleeding had less evidence of joint damage by 6 years of age than did those who were treated only after a bleed had started.
- About 70% of people with hemophilia in the United States receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers.
- Mortality rates and hospitalization rates for bleeding complications from hemophilia were 40% lower among people who received care in hemophilia treatment centers than among those who did not receive this care.
Treatment Product Safety
- Some of the products used to treat bleeds in people with hemophilia are made from plasma from donated blood. Manufacturing and viral inactivation steps have made these products very safe. A blood safety surveillance system in place since 1998 has found no new infections with hepatitis or HIV associated with these products among hemophilia patients.
- A recent study of young children with bleeding disorders found evidence for decreasing risk of childhood infection from plasma-derived clotting factor concentrates.
- Hispanic patients with severe hemophilia are about twice as likely to get an inhibitor than non-Hispanic white patients.
- A six-year study of patients in 17 US hemophilia treatment centers found that all patients with hemophilia can be at risk for an inhibitor and screening for an inhibitor is important.
- Prophylaxis decreases the risk of intracranial bleeding by 50% for people with hemophilia.
- People with hemophilia who learn how to treat their bleeds at home are less likely to be admitted to the hospital for a bleeding complication.
- CDC data have shown that in addition to increasing disease severity of hemophilia, being overweight, as measured by body mass index (BMI), is strongly associated with joint mobility limitations.
- Rates of overweight and obesity among children and adolescents with hemophilia are similar to those among the general population, which are currently at epidemic proportions.
- A study of more than 10,000 patients enrolled in the UDC surveillance project revealed that boys and men who were overweight or obese were less likely to infuse clotting factor at home.
- Women who are hemophilia carriers were found to have reduced joint range of motion compared to non-carrier women.
- People with hemophilia have unique risk factors that may predispose them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV.
- People with hemophilia have risk factors that have been associated with acute and chronic renal disease, such as HIV infection and kidney bleeding.
Inhibitors and Risk of Death
Does having an inhibitor increase your risk of death?
(Published April 2, 2015)
Hemophilia Carriers and Joint Abnormalities
New study finds evidence of joint abnormalities among hemophilia carriers.
(Published March 20, 2015)
Does the Level of Protection Against the Hepatitis B Virus Differ Based on the Way in Which the Vaccine is Given (for example, injected into a muscle or injected under the skin)?
(Published November 22, 2014)
Platelet Function Testing
Platelet function testing can determine the cause of excessive bleeding but is not well studied.
(Published May 1, 2014)
Hemophilia and Inhibitors
All people with hemophilia are at risk for developing inhibitors
(Published April 15, 2014)
What Is An Inhibitor?
Learn about inhibitors and read a personal story on living with an inhibitor.
(Published: March 19, 2018)
Making Strides Toward Preventing Inhibitors in Bleeding Disorders
CDC’s Division of Blood Disorders is committed to reducing the occurrence of inhibitors. Find out what they are doing to reach their goal.
(Published: April 17, 2017)
Do You Know About Bleeding Disorders?
Learn how you can support people with bleeding disorders.
(Published: March 13, 2017)
World Hemophilia Day 2016
Read and share the stories of people with hemophilia to raise awareness.
(Published: April 15, 2016)